Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01139346 · ClinicalTrials.gov registry record · Phase 1

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Alaunos Therapeutics.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
3
Study locations

NCT01139346 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Alaunos Therapeutics. The registered enrollment target is 12 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01139346, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Alaunos Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
3
Study locations

Study Summary

This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG darinaparsin

Study Locations (3)

Texas

  • - Dallas
  • - Houston

Indiana

  • - Lafayette

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2010-06
Est. Completion 2012-04
Phase Phase 1

Sponsor

Alaunos Therapeutics

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01139346

The ClinicalTrials.gov registry entry for NCT01139346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (94% lower). The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which darinaparsin is the first listed.

NCT01139346 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Indiana.

Frequently Asked Questions

What is clinical trial NCT01139346 about?

NCT01139346 is a clinical study titled "Study of Oral Darinaparsin in Patients With Advanced Solid Tumors". This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.

What is the current status of trial NCT01139346?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-06. Estimated completion is 2012-04.

What conditions does trial NCT01139346 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT01139346?

The interventions under investigation include: darinaparsin (DRUG).

Who is sponsoring clinical trial NCT01139346?

This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01139346 being conducted?

This trial has 3 study locations across Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.